L 683519
Latest Information Update: 07 Jun 2001
At a glance
- Originator Merck & Co
- Class Immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Immunosuppression in USA (Unknown route)
- 17 Jan 1995 Preclinical development for Immunosuppression in USA (Unknown route)